| [1] | Journal of Hepatology｜Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. Journal of Clinical Hepatology, 2024, 40(2): 257-257. doi: 10.12449/JCH2402.gwqkjpwzjj1 |
| [2] | Yang WANG, Hao LIAO, Zhongping DENG, Jing ZHAO, Dandan BIAN, Yan REN, Yingying JIANG, Shuang LIU, Yu CHEN, Fengmin LU, Zhongping DUAN, Sujun ZHENG. Value of combined baseline serum HBV markers in predicting HBeAg seroconversion in chronic hepatitis B patients treated by nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2023, 39(5): 1070-1075. doi: 10.3969/j.issn.1001-5256.2023.05.011 |
| [3] | Shiwan ZHANG, Xing CHEN, Jiao LIU, Min ZHAO, Xiaoping MEI. Expression levels of HBV pregenomic RNA and hepatitis B core-related antigen in circulating serum and their association with recurrence in chronic hepatitis B patients after withdrawal from nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2023, 39(1): 56-62. doi: 10.3969/j.issn.1001-5256.2023.01.009 |
| [4] | Hepatology International｜The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis[J]. Journal of Clinical Hepatology, 2023, 39(7): 1534-1534. doi: 10.3969/j.issn.1001-5256.2023.07.gwjpwzjj1 |
| [5] | Hanxiao WANG, Xinju CHEN, Qing ZHAO, Wenxia ZHAO. Role of traditional Chinese medicine in treatment of chronic hepatitis B by nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2022, 38(8): 1886-1891. doi: 10.3969/j.issn.1001-5256.2022.08.033 |
| [6] | Shan REN, Sujun ZHENG. An excerpt of APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients (2021)[J]. Journal of Clinical Hepatology, 2022, 38(1): 78-80. doi: 10.3969/j.issn.1001-5256.2022.01.011 |
| [7] | Jiacong SHEN, Xiaopeng LI, Xiaoyu CHENG, Yuanmei CHE, Wan LEI, Guanlin ZHOU, Lunli ZHANG. Prognosis of acute-on-chronic liver failure caused by hepatitis recurrence after withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients with different HBeAg status[J]. Journal of Clinical Hepatology, 2022, 38(1): 86-90. doi: 10.3969/j.issn.1001-5256.2022.01.013 |
| [8] | Fengming LU, Bo FENG, Sujun ZHENG, Suzhen JIANG, Ruifeng YANG, Junliang FU, Dong JI, Shuangsuo DANG, Xiaobo LU, Hongsong CHEN, Xinyue CHEN, Hong REN, Zhiliang GAO, Yuemin NAN, Xiaoyuan XU, Junqi NIU, Wenhong ZHANG, Hui ZHUANG. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2021, 37(6): 1268-1274. doi: 10.3969/j.issn.1001-5256.2021.06.007 |
| [10] | Jiang YingYing, Zheng SuJun. Research advances in predictive markers for HBeAg seroconversion in chronic hepatitis B patients treated with nucleos( t) ide analogues[J]. Journal of Clinical Hepatology, 2020, 36(6): 1358-1361. doi: 10.3969/j.issn.1001-5256.2020.06.036 |
| [11] | Ruan JianWen, Gao LiJuan, Su RuKai, Wang YaJiao, Yang Jing. Clinical effect of nucleos (t) ide analogues in treatment of acute exacerbation of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(6): 1251-1255. doi: 10.3969/j.issn.1001-5256.2019.06.014 |
| [12] | The Hepatitis Group, Chinese Society of Hepatology, Chinese Medical Association, Chinese Journal of Hepatology. An expert consensus for the adjustment of treatment strategies in patients with chronic hepatitis B treated with non-first-line nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2019, 35(6): 1212-1214. doi: 10.3969/j.issn.1001-5256.2019.06.008 |
| [13] | Wu XiaoFeng, Li YuFang, Zhang Chi, Zhang LiLi, Ma Ying. Influencing factors for compliance with antiviral therapy with nucleos(t) ide analogues in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(10): 2194-2199. doi: 10.3969/j.issn.1001-5256.2019.10.013 |
| [15] | Zhou YouQian, Li Cui, Yin FengMing, Zhang HaiYan, Ren Bin, Yang Wei. Change in HBsAg quantification after HBV DNA negative conversion in chronic hepatitis B patients treated with nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2019, 35(5): 977-981. doi: 10.3969/j.issn.1001-5256.2019.05.009 |
| [16] | Yuan Ling, Ceng BaiMei, Lin ShiDe. Research advances in the pathogenesis and diagnosis/treatment of muscle injury after treatment with nucleos (t) ide analogues in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(3): 627-630. doi: 10.3969/j.issn.1001-5256.2019.03.039 |
| [18] | Zhuang Hui, Weng XinHua. Optimal strategy for chronic hepatitis B patients receiving nucleos (t) ide analogue antiviral treatment[J]. Journal of Clinical Hepatology, 2011, 27(4): 340-342. |
| [19] | Chen ShiJun, Du WenJun. Re-treatment for relapsed patients after an initial nucleotide (s) analogue therapy in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(12): 1257-1258+1269. |
| [20] | Liang YanXiu, Jiang JianNing, Su MingHua, Guo WenWen, Huang XiaoHong, Liu ZhiHong, Xie Rong, Fu WuDao, He LiXia, Zhong ShaoHua. Influence of HBeAg seroconversion on virological relapse in chronic hepatitis B patients on withdrawal of nucleos (t) ide analogues therapy[J]. Journal of Clinical Hepatology, 2011, 27(12): 1275-1277+1290. |
DownLoad: